Faeth Therapeutics
Faeth Therapeutics

Faeth Therapeutics

Biotechnology
WebsiteInvestor RelationsSEC
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).

$891.5M

Market Cap • 9/18/2026

2017

(9 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

5,2

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

6,7

EPS

—

Market Cap

Market Cap

891,5M

EV

712,4M

EV/Revenue

0

EV/EBITDA

-3,6

EV/EBIT

-3,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,1%

Total Yield

-0,1%

Payout

0%

Retained Earnings

-469,4M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

5,3%

Capex/OCF

0%

SBC/OCF

—

% PPE

0,3%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

47,8%

CAGR Net Income 5Y

47,3%

CAGR EPS 5Y

-43,3%

CAGR OCF 5Y

6%

Leverage

N.D./EBITDA

0,9

Debt/Equity

0%

Current Ratio

19,7

Quick Ratio

19,5

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium